Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder

CBT Augmentation for SRI Pharmacotherapy in OCD

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00045903

Acronym

Aug1

Enrollment

136

Registered

2002-09-17

Start date

2000-08-31

Completion date

2007-01-31

Last updated

2014-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder

Keywords

Cognitive Behavioral Therapy

Brief summary

This study will evaluate the effectiveness of two cognitive behavioral therapies (CBTs) in treating obsessive compulsive disorder (OCD) in patients who are taking medication but still have residual symptoms.

Detailed description

Participants remain on their current OCD medication and are randomly assigned to receive one of two CBTs: exposure and ritual prevention or stress management therapy. Exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. Stress management involves relaxation, assertiveness training, and structured problem-solving. Therapy occurs twice per week for 2 months. Participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. Patients who respond are followed for up to 1 additional year. Participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. During the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication. For information on a related study, please follow this link: http://clinicaltrials.gov/show/NCT00389493

Interventions

BEHAVIORALExposure and Ritual Prevention (Cognitive Behavioral Therapy)

BEHAVIORALStress Management Therapy (Cognitive Behavior Therapy)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Obsessive-Compulsive Disorder (OCD) diagnosis * Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD

Exclusion criteria

* Medical or psychiatric conditions that would make participation in the study hazardous * Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD

Design outcomes

Primary

Measure	Time frame
Obsessive-compulsive symptoms measured at Month 2	2 months

Secondary

Measure	Time frame
General functioning measured at Month 2	2 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026